Here are some things to think about when buying one
Results from a later-stage study are expected in the first half of next year, according to Evan Seigerman, a research analyst with financial firm BMO Capital Markets
Thomas DM, Udagawa N, Hards DK, et al
Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)
In contrast, Noom states that their dosing starts at 25% or less of the standard 0.25 mg dose and escalates at a personalized rate. While microdosing GLP-1 medications may provide a more personalized experience, there are still questions regarding the safety of this practice as there are currently no published studies on the process, and the microdoses may come from a compounding pharmacy
And let me tell you, after just a few days of use, I was absolutely amazed